Connect your AI

Denali Therapeutics Inc. DNLI PP&E (Net)

PP&E (Net) at other companies

Eli LillyLLY

$26.54B+43.7%

uniQureQURE

$12.01M-33.6%

BridgeBio PharmaBBIO

$4.94M-26.2%

BiogenBIIB

$3.02B-3.7%

PTC TherapeuticsPTCT

$52.74M-11.3%

Dyne Therapeutics, Inc.DYN

$23.68M+312%

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.93B+54.2%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s PP&E (net)?: Denali Therapeutics Inc. (DNLI) reported PP&E (net) of $51.73M in Q1 2026.
How has Denali Therapeutics Inc.'s PP&E (net) changed year-over-year?: Denali Therapeutics Inc.'s PP&E (net) decreased by 10.5% year-over-year, from $57.77M to $51.73M.
What is the long-term trend for Denali Therapeutics Inc.'s PP&E (net)?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s PP&E (net) has grown at a 5.1% compound annual growth rate (CAGR), from $40.85M to $52.4M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.